Pfizer Embraces Biotech-Like Speed To Advance BCMA Bispecific
Phase II Pivotal Trial Under Way For Elranatamab In Multiple Myeloma
Executive Summary
Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.
You may also be interested in...
Multiple Myeloma Bispecifics Vie For Leadership Based On Safety, Combinability
Updates at ASH for bispecifics targeting BCMA, GPRC5D and FcRH5 from Regeneron, Janssen, Pfizer, Roche, AbbVie and Harpoon show monotherapy efficacy, initial combination data and potential safety differentiation.
Arvinas, Pfizer Partner To Pursue Best-In-Class Breast Cancer Strategy
Pfizer agreed to pay up to $2.4bn to share development and commercialization costs for Arvinas’ estrogen receptor degrader, including in combination with Ibrance.
How Pfizer Crafted Its Own ‘Operation Warp Speed’ For The COVID-19 Vaccine
It’s counter-intuitive, but not signing a commercial contract with BioNTech and refusing US federal funding were two of several moves Pfizer made to speed up development of its COVID-19 vaccine, CEO Albert Bourla says. Now it’s looking to supply low- and middle-income countries.